Short answer
Build demand capture rather than demand generation. When Meta and Google will not accept the category, growth has to come from organic search, owned audiences, practitioner referral, and the existing patient base. MedScale, which works exclusively with telehealth brands, treats this as the defining strategic problem for peptide businesses, because the channels that remain are slower to build and considerably harder for a competitor to take away.
Reframing the problem
Peptide brands typically arrive asking how to get ads approved. MedScale works only with telehealth brands, and the more productive question is how to grow without the channel, because for most of this category the answer to the first question is that you cannot, and time spent on it is time not spent building something that works.
There is a real compensation. Channels built under constraint are durable in a way paid acquisition is not. A competitor can outbid you tomorrow; they cannot take your organic position or your patient base as quickly.
Organic search is the primary channel
Peptide search demand is substantial and largely informational, which suits organic content precisely. Advertising policy does not govern organic pages, so content can address questions that paid creative cannot.
- Substance-specific questions people actually search, answered accurately including regulatory status.
- Comparison and protocol content, which carries high intent and is poorly served by existing sources.
- Clinical process content explaining what a consultation involves and who is eligible.
The constraint is that health claims still need to be defensible. Organic freedom from ad policy is not freedom from regulators or from the obligation to be accurate.
Owned audiences compound
Email and SMS lists are the most valuable asset a restricted-category brand can build, because they are the only distribution nobody can revoke. Every organic visitor who leaves without joining an owned audience is a permanent loss in a business that cannot simply retarget them.
This changes what the website is for. In a paid-led business the site converts; in a restricted-category business the site captures, and conversion happens over a longer relationship.
Practitioner and clinic referral
Peptides frequently reach patients through practitioners rather than direct discovery, which makes practitioner relationships a channel rather than a partnership afterthought. It is slower and less measurable than paid media, and it is not subject to advertising policy at all.
For brands with a genuine clinical proposition this is often the highest-quality demand available, because it arrives pre-qualified and with a trust transfer that paid traffic never has.
The adjacent category route
Where a brand also operates in an advertisable category, paid acquisition can build the patient relationship there, with peptides introduced later inside an existing clinical relationship rather than as the acquisition offer.
This has to be structured honestly. Advertising one category while intending to convert to another is a misrepresentation problem, and the intent tends to be visible in the funnel. The defensible version is a genuine multi-product clinical business where the acquisition offer is real.
What this means for the plan
A peptide growth plan that assumes paid acquisition will be solved is not a plan. The realistic version accepts a longer payback period, invests earlier in content and owned audiences, and treats practitioner relationships as infrastructure. MedScale builds against that shape rather than treating it as a holding pattern until the ads get approved.
Common questions
- 01How long does organic growth take for a peptide brand?
- Considerably longer than paid, typically measured in quarters rather than weeks before meaningful volume arrives. The compensation is durability: organic position and owned audiences are not removed by a policy change or outbid by a competitor overnight.
- 02Can I use influencers to promote peptides?
- Influencer content is subject to disclosure obligations and to the same rules on health claims and unapproved products, and platforms increasingly treat branded content as advertising. It is not a route around policy, and it introduces a party whose claims you control less well than your own.
- 03Is affiliate marketing viable for restricted categories?
- Affiliates raise the same difficulty, since claims made by third parties on your behalf can create exposure for the brand while being harder to monitor. Any affiliate programme in this category needs enforceable claim standards rather than a commission structure alone.
- 04Should I still build landing pages if I cannot advertise to them?
- Yes. Landing pages serve organic traffic, email campaigns and referral traffic, all of which remain available. The page's job shifts from converting paid clicks to capturing visitors into an owned audience you can reach again.
Last reviewed August 3, 2026. Platform policies change often; we re-verify every answer quarterly.